Premium
Metallothioneins are potential prognostic biomarkers in breast cancer patients (1048.11)
Author(s) -
Malepati Dhananjaya,
S Lakshminarasaiah
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1048.11
Subject(s) - breast cancer , medicine , oncology , cancer , breast carcinoma , metallothionein , pathology , cancer research , biology , biochemistry , gene
Metallothioneins (MTs) are highly conserved low molecular weight proteins. The main functions of MTs are binding, chelating and detoxification of various toxic substances. It also protects tissue damage from reactive oxygen species, radiation and mutagens. MTsexpression levels were evaluated in order to determine its role in different clinical stages of breast tumors during pre‐ and post‐ menopausal women. In the present study the expression levels of metallothioneinisoforms MT‐1F, MT‐1E and MT‐2A were assessed by semi‐quantitative PCR in breast carcinoma tissues of seventy two individuals. Similarly, MT levels were also quantified in non tumor breast tissue samples of respective individual subjects, during different clinical stages of pre‐and postmenopausal breast cancer patients through RT‐PCR technique. .The percentage of expression levels were quantified by integrative density value (IDV). As the stage progresses the selected MT isoforms expression also increases in both pre‐ and post‐ menopausal breast tumors. This indicates that the MTs expression is closely associated with pre and postmenopausal malignant tumors along with non tumor tissues. So, MT isoforms are promising prognostic biomarkers in the prospective patient studies and may be validated to establish MT assays for use in clinical practice. Therefore the MT assays may be used as the Diagnostic tools in the diagnosis and treatment of women breast cancer. Grant Funding Source : INDIAN GOVT. FUNDING AGENCIES